Mapping research trends in shared decision-making for type 2 diabetes mellitus: a bibliometric study.

TL;DR

A bibliometric analysis of 272 research publications found that shared decision-making (SDM) in type 2 diabetes is an expanding field growing at 14.5% annually, but research remains concentrated in Anglo-European institutions with minimal participation from the Global South, limiting the generalizability of findings to diverse patient populations.

What the Study Found

Shared decision-making, in which clinicians and patients jointly evaluate evidence and align treatment choices with individual values and circumstances, has become increasingly recognized as essential for type 2 diabetes management. This study mapped the scientific landscape of SDM research in T2DM by analyzing 272 peer-reviewed publications indexed in Web of Science, Scopus, and PubMed through December 2024, authored by 1,307 researchers across 412 institutions in 31 countries.

The research productivity trajectory reveals accelerating interest in the field. Publications increased at an annual rate of 14.5% over the 24-year period, with peak output occurring in 2023. This growth reflects broader recognition that type 2 diabetes requires ongoing, complex decisions spanning treatment initiation, therapy intensification, medication adjustments, and lifestyle modifications. The challenge lies not in having one "correct" answer, but in aligning clinical evidence with each patient's unique values, preferences, and life circumstances. Effective SDM theoretically bridges this gap by explicitly incorporating patient input into the decision process.

The intellectual and institutional landscape shows pronounced geographic concentration. The United States dominated research output and international collaborations, followed by the United Kingdom and the Netherlands. Mayo Clinic emerged as the most productive single institution with 82 articles, while researcher Victor Montori (Mayo Clinic) was identified as the most intellectually influential author based on citation patterns. The core journals publishing SDM diabetes research were Patient Education and Counseling and BMC Health Services Research, suggesting the field sits at the intersection of patient behavior and health systems implementation. This institutional clustering around major medical centers and high-income countries raises important questions about whose perspectives and contexts are shaping SDM frameworks.

Thematic analysis identified two distinct research clusters. Established topics center on patient decision aids and medication adherence, representing the consolidated knowledge base in this area. Emerging themes involve "minimally disruptive medicine," a newer conceptual framework emphasizing treatment plans that minimize burden and disruption to patients' daily lives. However, the authors note a critical limitation: collaboration in SDM research is concentrated in the Global North, with strong Anglo-European biases. This geographic skew means current SDM models may not adequately address health systems, cultural contexts, health literacy patterns, or resource constraints typical of the Global South, where the absolute burden of type 2 diabetes is rising fastest.

What This Means for You

This analysis provides a snapshot of the SDM research ecosystem rather than clinical evidence about whether SDM improves outcomes. Several practical implications emerge:

If you have type 2 diabetes and are making treatment decisions, be aware that while SDM frameworks are increasingly recommended by clinical guidelines, the evidence base supporting them comes predominantly from high-income settings. Your clinician's familiarity with SDM principles may vary depending on their training and institutional context. Explicitly asking questions about treatment options, your role in decision-making, and how different approaches fit your life circumstances reflects the SDM ideal, even if your healthcare setting doesn't use formal SDM protocols.

If you're researching diabetes management strategies, recognize that the published literature on SDM in type 2 diabetes may not fully represent implementation challenges or effectiveness in diverse healthcare systems. The concentration of research in affluent settings with established patient decision aid resources suggests gaps in understanding how SDM works (or doesn't) in resource-limited contexts.

For healthcare systems and policymakers, the growth rate and institutional clustering suggest both opportunity and risk. The 14.5% annual growth indicates expanding interest and investment, but the geographic concentration means that scaling SDM globally without local adaptation or input from underrepresented regions risks exporting models that may not be culturally appropriate or feasible.

The emergence of "minimally disruptive medicine" as a research theme is noteworthy because it directly addresses a barrier many patients face: treatment regimens that become too burdensome to follow. This represents intellectual evolution beyond simply involving patients in decisions to actively designing treatments around patients' capacity to implement them.

Study Details

Sources

Mapping research trends in shared decision-making for type 2 diabetes mellitus: a bibliometric study. *Frontiers in Health Services*. PubMed: 42291693